<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019148</url>
  </required_header>
  <id_info>
    <org_study_id>SU-11182009-4402</org_study_id>
    <nct_id>NCT01019148</nct_id>
  </id_info>
  <brief_title>Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa</brief_title>
  <official_title>Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <brief_summary>
    <textblock>
      Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in
      the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters
      and open wounds from minor trauma to their skin. We are screening subjects with RDEB to
      evaluate characteristics of the subjects and their cells in order to develop new strategies
      of therapy and determine whether subjects could be candidates for treatment studies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa</measure>
    <time_frame>4 years</time_frame>
    <description>Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa for future studies</description>
  </primary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Epidermolysis Bullosa Dystrophica</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Skin biopsies, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with RDEB by a local dermatologist who are medically stable enough to
        travel to Stanford University Medical Center. Patients should also be at least 7 years of
        age.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of RDEB by local dermatologist

          -  7 years of age or older

        Exclusion Criteria:

        -Medical instability limiting ability to travel to Stanford University Medical Center
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Tang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Irene Bailey-Healy</last_name>
    <phone>(650) 721-7149</phone>
    <email>baileyhi@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melissa Barriga</last_name>
    <email>mbarriga@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irene Bailey-Healy</last_name>
      <phone>650-721-7149</phone>
      <email>baileyhi@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Jean Tang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>M. Peter Marinkovich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Oro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 20, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Jean Yuh Tang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
    <mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

